SCHEMBL1351720

SCHEMBL1351720

O=c1c2ccccc2[se]n1-c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.74
HDAC6 Q9UBN7 2/20 0.74
KDM4E B2RXH2 1/20 0.74
MEN1 O00255 1/20 0.74
QSOX1 O00391 1/20 0.74
RGS12 O14924 1/20 0.74
PMM2 O15305 1/20 0.74
PLIN1 O60240 1/20 0.74
GMNN O75496 1/20 0.74
BBOX1 O75936 1/20 0.74
ALDH1A1 P00352 1/20 0.74
LMNA P02545 1/20 0.74
TP53 P04637 1/20 0.74
CYBB P04839 1/20 0.74
BCHE P06276 1/20 0.74
GLA P06280 1/20 0.74
POLB P06746 1/20 0.74
CYP3A4 P08684 1/20 0.74
CYP2D6 P10635 1/20 0.74
MAPT P10636 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193047 0.86 METAP2 (0.79) METAP2HDAC6KDM4EMEN1QSOX1
Ebselen SCHEMBL4406056 0.85 METAP2 (1.00) METAP2HDAC6KDM4EMEN1QSOX1
Ebselen SCHEMBL33829 0.85 METAP2 (1.00) METAP2HDAC6KDM4EMEN1QSOX1
Ebselen SCHEMBL29370082 0.85 METAP2 (1.00) METAP2HDAC6KDM4EMEN1QSOX1
SCHEMBL28783439 0.84 METAP2 (0.77) METAP2HDAC6KDM4EMEN1QSOX1
Ebselen SCHEMBL19064566 0.84 METAP2 (0.96) METAP2HDAC6KDM4EMEN1QSOX1
Ebselen SCHEMBL20678555 0.84 METAP2 (0.96) METAP2HDAC6KDM4EMEN1QSOX1
Ebselen SCHEMBL20477111 0.84 METAP2 (0.96) METAP2HDAC6KDM4EMEN1QSOX1
SCHEMBL10501773 0.83 METAP2 (0.70) METAP2HDAC6KDM4EMEN1QSOX1
SCHEMBL10501092 0.83 METAP2 (1.00) METAP2HDAC6KDM4EMEN1QSOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112110877-B Benzisoselenazolone derivative, preparation method and application thereof in anti-coronavirus medicament 青岛大学 2023-09-08 CN disclosed
US-11013730-B1 Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith THIOREDOXIN SYSTEMS AB (SE) 2021-05-25 US disclosed
US-10058542-B1 Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith THIOREDOXIN SYSTEMS AB (SE) 2018-08-28 US disclosed
US-20140088149-A1 BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF THIOREDOXIN SYSTEM AB. (SE) 2014-03-27 US disclosed
US-8592468-B2 Bacterial thioredoxin reductase inhibitors and methods for use thereof THIOREDOXIN SYSTEMS AB (SE) 2013-11-26 US disclosed
US-8426452-B2 Process for the treatment and prevention of diseases caused by fungi BILLACK BLASE CHRISTOPHER (US) 2013-04-23 US disclosed
US-20110288130-A1 BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF THIOREDOXIN SYSTEMS AB (SE) 2011-11-24 US disclosed
US-20090239913-A1 Process for the treatment and prevention of diseases caused by fungi BILLACK BLASE CHRISTOPHER 2009-09-24 US disclosed
US-20090005422-A1 BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF THIOREDOXIN SYSTEMS AB (SE) 2009-01-01 US disclosed
EP-0154851-B1 BENZISOSELENAZOLETHIONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS A. Nattermann & Cie. GmbH (DE) 1989-08-02 EP disclosed
EP-0165534-B1 S-(CARBAMOYL-PHENYLSELENYL) DERIVATIVES OF GLUTATHION AND OF AMINO MERCAPTOCARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1989-03-15 EP disclosed
US-4711961-A Benzisoselenazolethiones and process for the treatment of various diseases in humans A. NATTERMANN & CIE GMBH (DE) 1987-12-08 US disclosed
EP-0198277-A1 Diseleno-bis-benzamides of primary and secondary amines, processes for their production and pharmaceutical preparations containing them A. Nattermann & Cie. GmbH (DE) 1986-10-22 EP disclosed
US-4618669-A FOR CELL INJURIES CAUSED BY ACTIVE OXYGEN METABOLITES A. NATTERMANN & CIE GMBH (DE) 1986-10-21 US disclosed
EP-0165534-A2 S-(carbamoyl-phenylselenyl) derivatives of glutathion and of amino mercaptocarboxylic acids, process for their preparation and pharmaceutical preparations containing them A. Nattermann & Cie. GmbH (DE) 1985-12-27 EP disclosed
EP-0154851-A1 Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds A. Nattermann & Cie. GmbH (DE) 1985-09-18 EP disclosed
US-4418069-A Benzisoselenazolones and process for the treatment of rheumatic and arthritic diseases using them A. NATTERMANN & CIE GMBH (DE) 1983-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005422-A1 BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF GSR, PRDX3, TXNRD3 METAP2 1795/4885HDAC6 1090/4885KDM4E 3142/4885
US-20140088149-A1 BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF GSR, PRDX3, TXNRD3 METAP2 1795/4885HDAC6 1090/4885KDM4E 3142/4885
US-11013730-B1 Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith SELENOI, TST, SCLY METAP2 1704/4885HDAC6 823/4885KDM4E 4710/4885
US-20110288130-A1 BACTERIAL THIOREDOXIN REDUCTASE INHIBITORS AND METHODS FOR USE THEREOF GSR, PRDX3, TXNRD3 METAP2 1795/4885HDAC6 1090/4885KDM4E 3142/4885
US-20090239913-A1 Process for the treatment and prevention of diseases caused by fungi ABCB11, ATP1A1, MAN2B1 METAP2 1338/4885HDAC6 1587/4885KDM4E 3988/4885
US-10058542-B1 Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith SELENOI, TST, GSS METAP2 2771/4885HDAC6 1247/4885KDM4E 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.